Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. Its poor response to current treatment options in advanced stages and the need for efficient diagnosis in early stages call for the development of new therapeutic and diagnostic strategies. Some of them are based on the use of nanometric materials as carriers and releasers of therapeutic agents and fluorescent molecules, or even on the utilization of magnetic materials that provide very interesting properties. These nanoformulations present several advantages compared with the free molecular cargo, including increased drug solubility, bioavailability, stability, and tumor specificity. Moreover, tumor multidrug resistance has been decreased in some cases, leading to improved treatment effectiveness by reducing drug dose and potential side effects. Here, we present an updated overview of the latest advances in clinical research, in vivo studies, and patents regarding the application of nanoformulations in the treatment of CRC. Based on the information gathered, a wide variety of nanomaterials are being investigated in clinical research, even in advanced phases, i.e., close to reaching the market. In sum, these novel materials can offer remarkable advantages with respect to current therapies, which could be complemented or even replaced by these nanosystems in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Advances in colon-targeted nano-drug delivery systems: challenges and solutions
Naeem, M., Awan, U. A., Subhan, F., Cao, J., Hlaing, S. P., Lee, J., Im, E., Jung, Y., & Yoo, J.-W. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01219-0 · Cited by 248
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82 · cited 1×
“Finally, cetuximab and panitumumab can be inactive as a result of BRAF or PIK3CA gene mutations, or due to KRAS, ERBB2, or MET gene amplification, which prevent EGFR signaling (20).”
BackgroundFernández Montes, A., Martínez Lago, N., Covela Rúa, M., de la Cámara Gómez, J., González Villaroel, P., Méndez Méndez, J. C., Jorge Fernández, M., Salgado Fernández, M., Reboredo López, M., Quintero Aldana, G., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1903 · Cited by 38
Cited by
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A.-H. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02357-z · Cited by 239
Ünal, S., Can Öztürk, S., Bilgiç, E., Yanık, H., Korkusuz, P., Aktaş, Y., Benito, J. M., Esendağlı, G., & Bilensoy, E. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.010 · Cited by 25
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer
Shahzad, M., Hameed, H., Amjad, A., Khan, M. A., Qureshi, I. S., Hameed, A., Saeed, A., & Munir, R. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03482-0 · Cited by 7
Metadata
- Authors
- Cabeza, L., Perazzoli, G., Mesas, C., Jiménez-Luna, C., Prados, J., Rama, A. R., & Melguizo, C.
- Venue
- AAPS PharmSciTech
- Published
- 2020-06-26
- Volume
- 21
- Issue
- 5
- Pages
- 178-178
- ISSN
- 1530-9932 (ISSN-L)
- OpenAlex
- W3037316010
- Cited by
- 58
- References
- 6
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents. https://app.cochat.ai/papers/10.1208/s12249-020-01731-y
- The paper
- Cabeza, L., Perazzoli, G., Mesas, C., Jiménez-Luna, C., Prados, J., Rama, A. R., & Melguizo, C. (2020). Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents. AAPS PharmSciTech. https://doi.org/10.1208/s12249-020-01731-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.